Population pharmacokinetics of carbamazepine in adults with epilepsy

Pharmacotherapy

Volumn 18, Issue 2 I, 1998, Pages 273-281

  Graves, Nina M ^a   Brundage, Richard C ^a   Wen, Yandong ^a   Cascino, Greg ^b   So, Elson ^b   Ahman, Peter ^c   Rarick, John ^a   Krause, Sandra ^a   Leppik, Ilo E ^a,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

^c MARSHFIELD CLINIC   (United States)

^d MINCEP Epilepsy Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; FELBAMATE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADULT; AGING; ARTICLE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG MIXTURE; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CARBAMAZEPINE; DRUG THERAPY, COMBINATION; EPILEPSY; EVALUATION STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOBARBITAL; PHENYTOIN; PREDICTIVE VALUE OF TESTS; PROPYLENE GLYCOLS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0031918974     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Holmes GL. Critical issues in the treatment of epilepsy. Am J Hosp Pharm 1993;50(suppl 5):S5-16.
2. Morselli PL. Carbamazepine. Absorption, distribution and excretion. In: Levy RH, Mattson RG, Meldrum BS, eds. Antiepileptic drugs. New York: Raven Press, 1995:515-28.
3. Patsalos PN, Duncan JS. Antiepileptic drugs. A review of clinically significant drug interactions. Drug Saf 1993;9(3):156-84.
4. Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine. J Clin Psychopharmacol 1991;11(5):306-13.
5. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Early stage autoinduction of carbamazepine metabolism in humans. Eur J Clin Pharmacol 1994;47(4):355-60.
6. Liu H, Delgado MR. Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites. Ther Drug Monit 1994;16(5):469-76.
7. Liu H, Delgado MR. Improved therapeutic monitoring of drug interactions in epileptic children using carbamazepine polytherapy. Ther Drug Monit 1994;16(2):132-8.
8. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism. Role of CYP 3A4 and CYP 2C8 in 10,11 epoxide formation. Biochem Pharmacol 1994;47(11):1969-71.
9. Hartley R, Forsythe WI, McLain B, et al. Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children. Clin Pharmacokinet 1991;20(3):237-46.
10. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982;8:195-222.
11. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9(4):503-12.
12. Martin ES, Crismon ML, Godley PJ. Postinduction carbamazepine clearance in an adult psychiatric population. Pharmacotherapy 1991;11(4):296-302.
13. Riad LE, Chan KK, Wagner WE, Sawchuk RJ. Simultaneous first- and zero-order absorption of carbamazepine tablets in humans. J Pharm Sci 1986;75:897-900.
14. Riad LE, Sawchuk RJ. Absorptive clearance of carbamazepine and selected metabolites in rabbit intestine. Pharm Res 1991;8:1050-5.
15. Bonneton J, Iliadis A, Genton P, et al. Steady state pharmacokinetics of conventional versus controlled-release carbamazepine in patients with epilepsy. Epilepsy Res 1993;14:257-63.
16. Bourgeois BFD, Wad N. Carbamazepine-10,11-diol steady state serum levels and renal excretion during carbamazepine therapy in adults. Ther Drug Monit 1984;6:259-65.
17. Schaffler L, Bourgeois BFD, Luders HO. Rapid reversibility of autoinduction of carbamazepine. Epilepsia 1994;35:195-8.
18. Christiansen J, Dam M. Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand 1973;49:543-6.
19. Christiansen J, Dam M. Drug interaction in epileptic patients. In: Schneider H, Janz D, Gardner-Thorpe C, et al, eds. Clinical pharmacology of antiepileptic drugs. Berlin: Springer-Verlag, 1975:197-200.
20. Callaghan N, Duggan B, O'Hare J, O'Driscoll D. Serum levels of phenobarbitone and phenylethylmalonamide with primidone used as a single drug and in combination with carbamazepine or phenytoin. In: Johannessen SI, Morselli PL, Pippenger CE, et al, eds. Antiepileptic therapy, advances in drug monitoring. New York: Raven Press, 1980:307-13.
21. Liu H, Delgado MR. Interactions of phenobarbital and phenytoin with carbamazepine and its metabolites: concentrations, concentration ratios, and level-dose ratios in epileptic children. Epilepsia 1995;36:249-54.
22. Johannessen SI, Strandjord RE. The influence of phenobarbitone and phenytoin on carbamazepine serum levels. In: Schneider H, Janz D, Gardner-Thorpe C, et al, eds. Clinical pharmacology of antiepileptic drugs. Berlin: Springer-Verlag, 1975:201-05.
23. Rambeck B, May T, Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedications. Ther Drug Monit 1987;9:198-303.
24. Kroetz DL, Kerr BM, McFarland LV, et al. Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. Clin Pharmacol Ther 1993;53:306-15.
25. Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia 1989;30:225-9.
26. Albani F, Theodore WH, Washington P, et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 1991;32:130-2.
27. Wagner ML, Graves NM, Marienau K, et al. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia 1991;32:398-406.
28. Wagner ML, Remmel RP, Graves NM, Leppik IE. Effect of felbamate on carbamazepine and its major metabolites. Clin Pharmacol Ther 1993;53:536-43.
29. Liu H, Delgado, MR Browne RH. Interactions of valproic acid with carbamazepine and its metabolites concentrations, concentration ratios, and level/dose ratios in epileptic children. Clin Neuropharmacol 1995;18:1-12.
30. Cloyd JC, Lackner TE, Leppik IE. Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics. Arch Fam Med 1994;3:589-98.